Press Releases
![M-LIFE™ Multitargeting Cancer Drug Prospect MLS-222QLD Successfully Advancing Through Pre-Clinical Testing](https://m-lifesciences.com/wp-content/uploads/2022/04/atomwise-native-breaker-image-1020x675.jpg)
M-LIFE™ Multitargeting Cancer Drug Prospect MLS-222QLD Successfully Advancing Through Pre-Clinical Testing
M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing. This molecule is one of several...
![iCFO Capital recently partnered with Moskal Lifesciences to raise $3.5M seed funding](https://m-lifesciences.com/wp-content/uploads/2019/11/Screen-Shot-2019-11-11-at-12.54.24-PM-e1573495012290.png)
iCFO Capital recently partnered with Moskal Lifesciences to raise $3.5M seed funding
SAN DIEGO, CALIFORNIA, DECEMBER, 2021 - iCFO Capital recently partnered with Moskal Lifesciences, LLC to raise $3.5M seed funding for expand growth from iCFO Capital investor network in San Diego, California. Moskal Lifesciences, LLC uses Novel Algorithms to Identify...
![M-Life™ Novel IL-6 Molecules and Efficacy/Toxicity Data](https://m-lifesciences.com/wp-content/uploads/2021/01/Screen-Shot-2021-01-18-at-4.47.38-PM.png)
M-Life™ Novel IL-6 Molecules and Efficacy/Toxicity Data
https://www.biospace.com/article/m-life-reveals-il-6-efficacy-toxicity-trade-offs-for-novel-botanical-based-analog-molecules-/
![M-Life™ COVID-19 Cytokine Storm Repurposing Possibilities](https://m-lifesciences.com/wp-content/uploads/2020/10/Cytokine-Storm-Mod-No-Text-Website.jpg)
M-Life™ COVID-19 Cytokine Storm Repurposing Possibilities
https://www.biospace.com/article/m-life-adds-cytokine-storm-acting-drugs-to-its-list-of-prospective-repurposed-covid-19-drugs-/